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| INTRODUC TI ON
Gastrointestinal stromal tumors account for less than 1% of all gastrointestinal (GI) tumors and for approximately 5% of all sarcomas. 1 However, they are the most common (80%) mesenchymal tumors of the GI tract. Worldwide annual incidences are largely consistent, ranging between 11 and 19.6 per million population. 2 GIST originate from ICC or ICC-like stem cell precursors. 2 Age of onset ranges between teenage years to the 90s, with a peak onset age of 60 years. 3 The most common organ affected is the stomach (50%-60%) followed by small intestine (30%-35%), rectum (5%), and esophagus (<1%). 3 GIST often recur locally within the abdomen and/or are metastasized to the liver. 2 Prognosis for GIST has been assessed by risk stratification schemes, including the modified NIH classification. 4 This criterion, which considers tumor size, mitotic count, tumor location, and tumor rupture, is useful in identifying patients who might benefit from adjuvant therapy. 5 Most GIST contain gain-of-function mutations in one of the two receptor tyrosine kinase genes, KIT (75%-80%) and PDGFRA (5%-10%), resulting in conformational changes of the respective proteins to constitutively activate downstream signaling pathways, including RAS/RAF/MAPK and PI3K/AKT/mTOR. 2 The remaining 10%-15% of GIST without KIT or PDGFRA mutations show different clinical and pathological features from the mutation-carrying GIST, and these so-called wild-type GIST include neurofibromatosis-type 1NF1, Carney triad, and Carney-Stratakis syndrome. 3 Discovery of TKI, including imatinib 6 and sunitinib, 7 targeting these oncogenic mutants, made a significant clinical impact on the drug treatment for GIST patients. Different types of mutations, including point mutations, deletions, and insertions can be found in the different exons of KIT and PDGFRA, and these mutations show type-and locationspecific relationships with risk stratification, clinical manifestations, and drug response. For example, GIST patients carrying KIT exon 11 deletion mutations show poor prognosis, 8, 9 but are sensitive to imatinib. 10 In KIT, oncogenic mutations found in exons other than exons 9 and 11 show primary resistance to imatinib, and some mutations in these regions arose from first-line treatment as secondary resistant mutations. 2, 11 Thus, second-or third-line drug treatment is carried out for patients showing resistance to TKI.
Anderson et al and others have suggested that KIT/PDGFRA mutations are very common events in the early stage of GIST development, and are not sufficient for GIST progression, and that other genetic changes are required for clinical manifestation. [12] [13] [14] Several chromosomal changes, including deletions in chromosome arms 1p, 13q, 14q, 15q, and 22q, [14] [15] [16] [17] and gains in chromosomes 4 and 5, 16, 17 have been associated with malignant progression of GIST. However, there are no consensus genetic alterations with mutations, amplification, or deletion for GIST development. 13 Thus, we aimed to identify driver gene alterations and the subsequent signaling pathways that drive the progression of GIST in order to develop effective therapies, particularly for TKI-resistant patients.
| MATERIAL S AND ME THODS

| Clinical samples
Tumor tissue samples dissected from surgical specimens, along with whole blood samples were obtained from Shizuoka Cancer Center under protocols approved by the institutional review board at Shizuoka Cancer Center (authorization number: [25] [26] [27] [28] [29] [30] [31] [32] [33] . 18 Written informed consent was obtained from all patients enrolled in the study. All experiments using clinical samples were carried out in accordance with the approved guidelines.
| Sequencing analysis
Isolation and characterization of genomic DNA for WES and CCP has been described previously. 19, 20 with a Custom Hotspot file that specifies somatic and pathogenic mutations registered in COSMIC and ClinVar, respectively. The list of identified mutations was processed by in-house scripts to remove false-positive calls, including sequencer-derived errors.
Mutations fulfilling at least one of the following criteria were dis- Thermo Fisher Scientific), and then blood data were analyzed by TVC with custom hotspot, which specifies all detected mutations in a tumor sample to determine whether these mutations were observed in the blood sample. Because a different variant caller and higher depth were used compared to those used for WES, the following criteria were used to identify unreliable mutations: (i) quality score <50; (ii) depth of coverage <20; or (iii) mutation matches one on an in-house false-positive list.
Effects of mutations were predicted using SnpEff. 21 Nonsynonymous mutations, including substitutions, insertions or deletions at coding regions and splice-sites were visually confirmed on the IGV, 22 and subsequently validated by Sanger sequencing. PCR and Sanger sequencing were carried out as described previously, 23 and primer sequences are shown in Table S1 . Based on the number of WES reads, CNA was calculated according to the saasCNV method. 24 We defined gain and loss in the case of copy number as ≥2.5 and <1.5, respectively. WES data were applied to estimate tumor purity using an in silico method. 25 Data of SNV and INDEL from WES and CCP are listed in Data S1. CNA data from WES are listed in Data S2. For fusion gene analysis, total RNA was used as a template to prepare cDNA, and subjected to the Ion Proton System for detecting fusion transcripts from a panel of 491 fusion genes, as previously reported. 26 
| Gene expression analysis
Total RNA was isolated and subjected to microarray analysis as described previously 18 using SurePrint G3 Human Gene Expression 8 × 60K v2 Microarray (Agilent Technologies). RNA samples with RNA integrity number ≥5.9 were used for microarray analysis.
Microarray analysis was carried out in accordance with the MIAME guidelines. 27 Data analysis was carried out using GeneSpring GX (Agilent Technologies), Subio platform (Subio), and Microsoft Excel.
Probes to be analyzed were selected according to the reference genome sequence, hg19, obtained from the UCSC Genome Browser. 28 Raw signal intensity values were log-transformed and normalized to the 75th percentile. Microarray data for mRNA expression are available through the NCBI database under accession GSE13 6755.
| Statistical analysis
We used Fisher's exact test for comparison of two datasets. Welch's t test was carried out in the assumed normal distribution. P-values <0.05 were considered statistically significant. We used the Z-score, which indicates the number of standard deviations away from the mean of expression, to predict significant changes in gene expression.
| RE SULTS
| Patient and tumor sample characteristics
A total of 65 surgically resected GIST tumor samples were obtained from 64 patients, which included six metastatic and 59 primary tumors (Table S2) (Tables S2 and S3 ), we identified oncogenic KIT and PDGFRA mutations in 57 (88%) and six (9%) of the 65 GIST samples, respectively. Among the KIT driver mutations, short deletions in exon 11 were observed more frequently (P = 8.5 × 10 −3 ) in the metastatic/high-risk groups (15 of 23 tumors) than in the other risk groups (15 of 42 tumors), as reported previously. 8, 9 In addition to the drivers, secondary KIT mutations, 2,11 including V654A in exon 13, T670I in exon 14, and N822Y in exon 17, were identified in three samples. CNA data by WES showed copy number gain of KIT in eight samples, of which a sample was from KIT/PDGFRA wild type ( Figure S1 ). Three samples showed copy neutral loss of heterozygosity (cnLOH) in KIT. GEP showed that KIT mRNA expression levels were lower in samples harboring PDGFRA mutations than in those with KIT mutations (P = 1.8 × 10 −2 ), whereas PDGFRA mRNA levels were lower in samples harboring KIT mutations than in samples with PDGFRA mutations (P = 4.0 × 10 −4 ). These observations were consistent with a previous report. 17 No correlation (P = 2.8 × 10 −1 ) was observed in KIT expression levels between samples with (copy number ≥2.5) or without (copy number = 2) KIT copy number gain. Even excluding samples harboring PDGFRA mutations, this conclusion was unchanged (P = 6.0 × 10 −1 ).
| Summary of WES and CCP
Mean depths of coverage for blood and tumor tissue sequences in WES were 131 (range, 94-164) and 126 (range, 93-126), respectively.
In CCP, mean depth of tumor tissue sequences was 1183 (range, 851-1438). Total numbers of nonsynonymous mutations in WES and CCP were 1084 (mean, 16.7) and 213 (mean, 3.3), respectively.
Among the 1084 mutations from WES, 113 mutations were derived from 409 CCP genes, and 85 out of 113 mutations (75.2%) were also detected in CCP. In contrast, 39.9% of mutations detected in CCP (85 out of 213) matched mutations detected by WES. Size of TMB, defined as the total number of synonymous/nonsynonymous mutations per megabase obtained from WES, ranged from 0.06 to 1.75 with a median of 0.77 ( Figure S1 ), indicating no TMB-high (TMB ≥20) samples in this set of GIST samples. 19 In addition to the GIST-initiating mutations of KIT and PDGFRA, we used WES and CCP data to investigate other genetic alterations against GIST progression, including SNV and INDEL of the 707 driver genes (Table S4 and Data S1) that were selected referring to several publications [29] [30] [31] 
| Oncogene mutations
In the case of the 406 OG, 29 mutations in 23 genes, consisting of 21 and eight mutations from 320 OG and 86 OG/TSG, respectively, were observed in 24 of the 65 samples ( Figure 1 ). Among them, PIK3CA mutations, including G106R (observed in a metastatic sample, no. 1) and R88Q (observed in paired primary and metastatic samples, nos 6.1 and 6.2), were the only mutations that have been identified as activating mutations. 33, 34 Of the remaining 26 mutations, MUC4, HDAC1, and MUC16 mutations were found in multiple samples, but the mutation patterns in each gene were different. Additionally, we also carried out fusion gene analysis and identified the oncogenic COL1A1-PDGFB fusion transcript 35 in an intermediate-risk sample (no. 33) ( Figure 1 ).
Taken together, the observations in the two patients with either metastasis or high-risk GIST suggests that PIK3CA mutations are possible driver alterations for malignant progression of GIST.
| Tumor suppressor gene dysfunction by LOH
Oncogenes initiate carcinogenesis when mutations dominantly occur within a single copy of the gene, whereas TSG are required to follow Knudson's 'two-hit hypothesis' to recessively inactivate the gene. 36 In addition to the classical TSG inactivation, even partial TSG inactivation, as a result of haploinsufficiency, or dominant-negative TSG mutations could contribute to tumorigenesis. [36] [37] [38] TSG inactivation is also due to epigenetic mechanisms of gene silencing (eg, hypermethylation of CpG islands located in the promoter region). 39 Thus, we investigated TSG dysfunction considering the following Considering the locations, all the four nonsense mutations found in RB1, MGA, and CBL (Table 1) were predicted to be nonfunctional by NMD. However, it is unclear whether the missense mutations play tumor-suppressive roles. In addition, the effect of copy number loss on mRNA expression was assessed by GEP data. As summarized in Table 1 , all of the seven deleterious mutations found in RB1, PTEN, TSC1, MGA, and CBL showed reduced expression levels (Z-score <0), which were designated as 'very likely' for TSG inactivation. One of the two RB1 mutations was copy neutral LOH. GIST showed a higher proportion in tissues (65%, 13 of 20) other than the stomach (22%, 10 of 45; P = 1.6 × 10 −3 ). Accordingly, the presence of LOH was higher in GIST from other tissues (35%, 7 of 20) than in GIST from the stomach (11%, 5 of 45; P = 3.6 × 10 −2 ).
| Tumor suppressor gene dysfunction by other alterations
Among the five TSG harboring deleterious mutations without copy number loss (copy number ≥1.5), a frameshift mutation in RBM10
showed reduced mRNA expression level (Table S5 ). This result indicates that mutation of RBM10, an RNA-binding protein and splicing regulator, has a tumor-suppressive role. Genes with the remainder of the four deleterious mutations, along with 27 genes harboring the missense and in-frame deletion mutations, can disrupt tumor-suppressive function of protein by haploinsufficiency or dominant-negative effect. However, according to the ACMG standards and guidelines 42 described previously, the nonsense USP44 mutation was predicted to maintain its function as a result of its location on the penultimate exon. Thus, considering the types of mutations and locations, four deleterious mutations in RBM10, CHD2, MGA, and MAML3 were designated as 'very likely'
for TSG inactivation. However, these mutations may not directly contribute to tumor growth and progression of GIST, commonly referred to as passenger mutations.
Next, we integrated TSG inactivation by genes carrying copy number loss with expression reduction. This corresponds to TSG inactivation as a result of copy number loss in one of the alleles and expression reduction, due to epigenetic changes (eg, promoter methylation) in the other allele. TSG showing copy number loss (copy number <1.5) and expression reduction (Z-score ≤−2.5) were observed in 55 genes with a total of 66 alterations ( Figure S2 ).
Four of these cases were identified as LOH-related TSG ( Table 1 ).
In GIST, deletions in chromosome arms 1p, 13q, 14q, 15q, and 22q are frequently observed, [14] [15] [16] [17] and were also observed in our samples ( Figure S3 ). Particularly, our CNA data showed preferential copy number loss at 13q in the metastatic/high-risk GIST samples.
Among the genes, expression reduction of RB1 was observed in multiple cases, including in two metastatic and one high-risk tumors ( Figure S2 ). This observation was consistent with the previous report that deletion at the RB1 locus frequently occurred in recurrent or metastatic GIST. 43 Last, we integrated TSG inactivation by genes showing expression reduction without copy number loss. This corresponds to TSG inactivation as a result of epigenetic modifications in both alleles.
TSG showing expression reduction (Z-score ≤−2.5) without copy number loss (copy number ≥1.5) were observed in 112 genes with a total of 150 alterations ( Figure S4 ). Seven genes, including ASXL2, ARID1B, EXT1, CREB3L1, FANCF, NPRL3, and SMARCE1, were downregulated in multiple samples of either metastatic or high-risk tumors. TGFBR2, RUNX1TX, CDKN1B, and CDH1 showed expression reduction in multiple samples from either metastatic or high-risk tumors along with low-risk tumor samples.
| Oncogene amplification
Oncogenes are activated by mutations, amplification, and chromosomal rearrangements, causing either an alteration in oncogene structure or an increase in or deregulation of its expression. 44 In addition to mutation and fusion gene identification, amplification of OG were investigated. Our previous report showed that amplified genes are not always upregulated. 18 Thus, we integrated GEP data with CNA data to assess OG amplification. Among the 406 OG, 98 genes showed copy number gain (copy number ≥2.5) accompanied by expression enhancement (Z-score ≥1.5; Figure S5 ).
Copy number gains of chromosomes 4 and 5 are frequently observed in GIST, 16, 17 which were also shown in our samples ( Figure   S3 ). Additionally, our data showed gains of chromosome 20q in the metastatic/high-risk GIST samples, in which expression levels of PLCG1, ZNF217, and GNAS were enhanced in the metastatic or high-risk tumor samples. Other OG, which were identified in multiple tumor samples from independent metastatic/high-risk patients, included SKP2, HOXA9, EZH2, CDK4, HMGA2, and FZD10.
| Integration of activated OG and inactivated TSG
We summarized the activated OG and inactivated TSG in each tumor sample ( Figure 2 ). Based on the types of alterations in OG and TSG, their effects on driver potential were classified into two types, including higher potential ('very likely') and lower potential ('possible'), as follows. The 'very likely' alterations were: (i) OG (PIK3CA) mutations known as activating mutations (Figure 1) ; (ii)
OG amplified with increased expression ( Figure S5 ); (iii) nonsense or frameshift TSG mutations with LOH (Table 1) ; (iv) frameshift TSG (RBM10) mutation with reduced expression (Table S5 ); (v) frameshift TSG mutations without reduced expression (Table S5 ); (vi) TSG with copy number loss and reduced expression ( Figure S2 ); (vii) TSG with reduced expression ( Figure S4 ); (viii) oncogenic fusion transcripts ( Figure 1 ). The 'possible' alterations were: (i) OG mutations with unknown function ( Figure 1 ); (ii) mutations found in genes defined as OG/TSG ( Figure 1) ; (iii) missense TSG mutations with LOH (Table 1) ;
(iv) missense TSG mutations (Figure 1) . 'Very likely' driver gene alterations with showed higher incidence in the metastatic/high-risk showing copy number gain (copy number ≥2.5) and expression enhancement (Z-score ≥1.0) in sample no. 9 were extracted from the genes significantly upregulated (fold change ≥2, P < .05) in the metastatic/high-risk GIST samples ( Figure 3B) . The 14 upregulated genes were located on chromosomes 4q or 20q, where copy number was gained in sample no. 9 ( Figure S3 ). As a potential TSG, only BANK1 was extracted as a gene showing expression reduction in sample no. 9 among the genes significantly downregulated (fold change ≤0.5, P < .05) in the metastatic/high-risk GIST samples ( Figure 3B ). For all 15 potential driver genes, no significant difference in expression level was observed between the metastatic and high-risk tumors (P > .05).
| Signaling pathway activation
Understanding of the genes along with pathways altered in tumor samples is essential to identify potential therapeutic options and vulnerabilities. According to the published information, 30, 31 we determined a pathway related to each driver gene (Table S4 ). Then, we assigned driver genes with alterations as 'very likely' driver potential ( Figure 2 has been reported to be activated as a result of imatinib secondary resistance. 42, 45, 46 In the present study, we observed PI3K pathway alteration even in tumor samples derived from patients not treated with neoadjuvant imatinib. In the metastatic/high-risk tumor samples, the alterations in PI3K and cell cycle pathways were not significantly related to neoadjuvant imatinib (P = 4.1 × 10 −1 , P = 4.2 × 10 −1 , respectively).
| D ISCUSS I ON
KIT or PDGFRA mutations activate most GIST (~90%). However, their prognosis and development are independent of the types of mutation. Thus, these mutations are believed to be early events in GIST development, which involves additional genetic alterations for malignant progression. [12] [13] [14] Saponara et al reported that metastatic GIST showed frequent copy number loss at regions located on TSG, although no shared oncogenic mutations were observed except in KIT. 13 In the present study, despite the fact that there were no common mutations in driver genes of GIST with the maximum frequency of 5%, we showed that PI3K and cell cycle signaling pathways were involved in GIST malignant progression. mutations and copy number gain with expression enhancement in AKT1 and RICTOR, and tumor-suppressive inactivation by LOH or expression reduction of TSC1/2, and NPRL3 ( Figure S6 ). The PI3K pathway has been reported to be activated as a result of imatinib secondary resistance, including GIST. 42, 45, 46 In the present study, we observed PI3K pathway alteration even in tumor samples derived from patients who were not treated with neoadjuvant imatinib, suggesting that PI3K activation was irrelevant to imatinib treatment in CDKN2A gene leads to upregulation of E2F1, increasing cell proliferation to drive poor prognosis for GIST. 47 Saponara et al reported that copy number losses of CDKN2A and CDKN2B were the most frequent in metastatic GIST. 13 We also observed significant losses of CDKN2A
and CDKN2B in metastatic and high-risk GIST compared with the other risk GIST (P = 6.4 × 10 −3 ). However, as a result of insufficient decreased mRNA levels, these genes were not identified as altered TSG.
Inactivating mutations of other cell cycle pathway genes, including RB1 and TP53, occur in high-risk GIST, showing activation of the cell cycle pathway. 48, 49 We also observed inactivation of RB1, but not of TP53. CDKN1B, another TSG, was downregulated in two samples from each metastasis and high-risk GIST group. As CDKN1B is suppressed by AKT, 2 the cell cycle pathway can cooperate with the PI3K pathway.
F I G U R E 5 Genetic alterations and expression modulations of PI3K pathway-related genes. A, Expression levels of SNAI1, TPX2, and BANK1. Expression data were added to the data on the PI3K pathway shown in Figure 4A . B, Overview of the PI3K pathway with involvement of SNAI1, TPX2, and BANK1. Interactions between genes were deduced based on published articles. 50, 51, 53 We identified 15 potential driver genes from a GIST sample (no. 9) without alterations in the 707 known driver genes. Analysis of associated pathways showed that SNAI1, TPX2, and BANK1 were involved in the PI3K pathway. SNAI1, a zinc-finger transcription factor, promoted cell migration through downregulation of SERPINB5 (Maspin) and subsequent activation of PI3K/AKT-dependent Rac1 during prostate cancer progression. 50 TPX2, targeting protein for Xklp2, which is a microtubule-associated protein, suppressed proliferation through repressing the PI3K/AKT signaling pathway in breast cancer cells. 51 Downregulation of BANK1 promoted CD40dependent AKT activation in B cells. 52, 53 Collectively, in sample no.
9, SNAI1 and TPX2 were activated by amplification-dependent expression enhancement, and BANK1 was inactivated by expression reduction. Among other metastatic/high-risk GIST, 12 and nine samples were upregulated (Z-score ≥1.0) without copy number gain for SNAI1 and TPX2, respectively ( Figure 5A ). Two more metastatic/ high-risk GIST showed reduced expression (Z-score ≤−2.5) of BANK1.
Based on activated AKT ( Figure 5B ), insertion of these results into the alteration data identified that 20 (87%) of the 23 metastatic/ high-risk samples were involved in the PI3K pathway, suggesting that its activation drives malignant progression of GIST. In fact, the PI3K pathway has been implicated in metastasis for various types of tumors (review in ref 54 ).
In summary, using multi-omics analysis, we identified driver gene alterations and subsequent signaling pathways. Our data indicate that the PI3K and cell cycle pathways play important roles in GIST malignant progression, which can be of significance for prognosis and treatment of GIST. Particularly, we propose that the development of PI3K inhibitors 55 is of potential benefit for patients with metastatic/high-risk GIST.
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